Anti-reflux Mucosectomy (ARMS) is a Useful Therapy for Refractory Gastroesophageal Reflux Disease (RGERD)
Launched by RUIHUA SHI · Aug 20, 2017
Trial Information
Current as of July 04, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Full sufficiency in literacy
- • 2. Be off proton pump inhibitor, antacids and prokinetics ≥ 2 weeks
- • 3. Refractory gastroesophageal reflux disease
- Exclusion Criteria:
- • 1. Severe heart, lung, and cerebrovascular disease
- • 2. Severe hematopoietic system disease
- • 3. Abnormal blood coagulation function
- • 4. Oropharyngeal abnormalities
- • 5. Severe spine malformation
- • 6. In pregnancy and lactation at present, or plan to become pregnant within 2 years
- • 7. Severe inflammation or huge ulcers in stomach
- • 8. Mental and psychological disorde
About Ruihua Shi
Ruihua Shi is a distinguished clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing novel therapeutics across various therapeutic areas, Ruihua Shi employs a rigorous approach to clinical development, ensuring adherence to the highest regulatory standards and ethical practices. The organization collaborates with leading researchers and institutions to facilitate cutting-edge studies, aiming to improve patient outcomes and contribute to the global healthcare landscape. Through commitment to scientific excellence and patient safety, Ruihua Shi is poised to make significant strides in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Trial Officials
Huiping Wang
Study Chair
Zhongda Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials